Celecoxib: a review of its use in the management of arthritis and acute pain (Q34584630)

3 August 2017

1 reference

title

Celecoxib: a review of its use in the management of arthritis and acute pain (English)

1 reference

3 August 2017

0 references

1 reference

ChEBI release 2020-05-28

2

Gillian M Keating

1 reference

3 August 2017

James E Frampton

1

1 reference

3 August 2017

1 January 2007

1 reference

3 August 2017

1 reference

3 August 2017

67

1 reference

3 August 2017

16

1 reference

3 August 2017

2433-2472

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767160-00008

3 August 2017

0 references

cites work

Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00008

Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00008

Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00008

Celecoxib is as efficacious as naproxen in the management of acute shoulder pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00008

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00008

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00008

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003495-200767160-00008

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials

21 January 2018

1 reference

12 December 2020

RETRACTED: The effect of initiating a preventive multimodal analgesic regimen on long-term patient outcomes for outpatient anterior cruciate ligament reconstruction surgery

1 reference

12 December 2020

Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib?

1 reference

12 December 2020

Clinical implications of drug interactions with coxibs

1 reference

12 December 2020

Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies

1 reference

12 December 2020

Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib

1 reference

12 December 2020

An economic model of long-term use of celecoxib in patients with osteoarthritis

1 reference

12 December 2020

Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction

1 reference

12 December 2020

Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database

1 reference

12 December 2020

Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications

1 reference

12 December 2020

Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment

1 reference

12 December 2020

Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin

1 reference

12 December 2020

Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study

1 reference

12 December 2020

Analgesia for day-case surgery

1 reference

12 December 2020

Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain

1 reference

12 December 2020

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

12 December 2020

Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

The burden of musculoskeletal disease--a global perspective

1 reference

12 December 2020

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

1 reference

12 December 2020

The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain

1 reference

12 December 2020

Efficacy and tolerability of celecoxib versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults

1 reference

12 December 2020

A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib

1 reference

12 December 2020

Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

1 reference

12 December 2020

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Guidelines for the management of rheumatoid arthritis: 2002 Update

1 reference

12 December 2020

A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model

1 reference

12 December 2020

The burden of ankylosing spondylitis.

1 reference

12 December 2020

Selective cyclooxygenase-2 inhibitors: similarities and differences

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Update on the role of nonsteroidal anti-inflammatory drugs and coxibs in the management of acute pain

1 reference

12 December 2020

Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis

1 reference

12 December 2020

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

12 December 2020

Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial

1 reference

12 December 2020

Effect of short-term postoperative celecoxib administration on patient outcome after outpatient laparoscopic surgery

1 reference

12 December 2020

Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo‐controlled trial

1 reference

12 December 2020

Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships

1 reference

12 December 2020

Limitations of NSAIDs for pain management: Toxicity or lack of efficacy?

1 reference

12 December 2020

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

1 reference

12 December 2020

Determine whether perioperative celecoxib administration would reduce opioid consumption and provide effective pain relief in patients undergoing arthroscopic knee surgery

1 reference

12 December 2020

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

1 reference

12 December 2020

Clinical pharmacology of novel selective COX-2 inhibitors

1 reference

12 December 2020

Celecoxib and cardiovascular risks

1 reference

12 December 2020

Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study

1 reference

12 December 2020

EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)

1 reference

12 December 2020

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

1 reference

12 December 2020

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

12 December 2020

EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

12 December 2020

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

12 December 2020

Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?

1 reference

12 December 2020

Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial

1 reference

12 December 2020

Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors

1 reference

12 December 2020

New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study

1 reference

12 December 2020

Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors

1 reference

12 December 2020

Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors

1 reference

12 December 2020

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

1 reference

12 December 2020

Persistence with COX-2 inhibitors in managed care: an analysis of claims data

1 reference

12 December 2020

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

12 December 2020

Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib.

1 reference

12 December 2020

Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema

1 reference

12 December 2020

Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac

1 reference

12 December 2020

Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing

1 reference

12 December 2020

Update on guidelines for the treatment of chronic musculoskeletal pain

1 reference

12 December 2020

Inhibitors of cyclooxygenases: mechanisms, selectivity and uses

1 reference

12 December 2020

Celecoxib for the prevention of colorectal adenomatous polyps

1 reference

12 December 2020

Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications

1 reference

12 December 2020

Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis

1 reference

12 December 2020

Summing the risk of NSAID therapy

1 reference

12 December 2020

Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain

1 reference

12 December 2020

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies

1 reference

12 December 2020

Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis.

1 reference

12 December 2020

Safety and efficacy of oral nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis : a six-month randomised study

1 reference

12 December 2020

Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.

1 reference

12 December 2020

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

1 reference

12 December 2020

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

1 reference

12 December 2020

Celecoxib for the prevention of sporadic colorectal adenomas

1 reference

12 December 2020

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

1 reference

12 December 2020

Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial

1 reference

12 December 2020

Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population

1 reference

12 December 2020

COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management

1 reference

12 December 2020

The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib

1 reference

12 December 2020

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

1 reference

12 December 2020

Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs

1 reference

12 December 2020

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

1 reference

12 December 2020

Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial

1 reference

12 December 2020

Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis

1 reference

12 December 2020

Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial

1 reference

12 December 2020

Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

1 reference

12 December 2020

Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.

1 reference

12 December 2020

Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial

1 reference

12 December 2020

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis

1 reference

12 December 2020

Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-control study

1 reference

12 December 2020

Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

1 reference

12 December 2020

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

1 reference

12 December 2020

Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.

1 reference

12 December 2020

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

12 December 2020

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

1 reference

12 December 2020

Effect of ibuprofen on cardioprotective effect of aspirin

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

1 reference

12 December 2020

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

12 December 2020

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

1 reference

12 December 2020

Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects.

1 reference

12 December 2020

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

12 December 2020

The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin

1 reference

12 December 2020

Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial

1 reference

12 December 2020

COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study

1 reference

12 December 2020

American pain society pain questionnaire and other pain measures in the assessment of osteoarthritis pain: a pooled analysis of three celecoxib pivotal studies

1 reference

12 December 2020

Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect?

1 reference

12 December 2020

A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain

1 reference

12 December 2020

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

1 reference

12 December 2020

The safety of celecoxib in patients with aspirin-sensitive asthma

1 reference

12 December 2020

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

1 reference

12 December 2020

EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

12 December 2020

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

1 reference

12 December 2020

Upper gastroduodenal ulceration in arthritis patients treated with celecoxib

1 reference

12 December 2020

OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence

1 reference

12 December 2020

Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry

1 reference

12 December 2020

Selective COX-2 inhibition improves endothelial function in coronary artery disease

1 reference

12 December 2020

Update on nonsteriodal anti-inflammatory drugs

1 reference

12 December 2020

Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice

1 reference

12 December 2020

Parecoxib (parecoxib sodium).

1 reference

12 December 2020

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

1 reference

12 December 2020

Basic biology and clinical application of specific cyclooxygenase-2 inhibitors

1 reference

12 December 2020

Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

Decisions by regulatory agencies: are they evidence-based?

1 reference

12 December 2020

The double-edged sword of COX-2 selective NSAIDs

1 reference

12 December 2020

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.

1 reference

12 December 2020

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association

1 reference

12 December 2020

Coxibs and heart disease: what we have learned and what else we need to know

1 reference

12 December 2020

Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction

1 reference

12 December 2020

Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?

1 reference

12 December 2020

Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk

1 reference

12 December 2020

Cyclooxygenase-2 inhibition and renal physiology

1 reference

12 December 2020

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

1 reference

12 December 2020

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

1 reference

12 December 2020

Relationship between COX-2 specific inhibitors and hypertension

1 reference

12 December 2020

Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction

1 reference

12 December 2020

Immunologic tolerability profile of celecoxib

1 reference

12 December 2020

Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk

1 reference

12 December 2020

Analgesic efficacy of perioperative celecoxib in ambulatory arthroscopic knee surgery: a double-blind, placebo-controlled study.

1 reference

12 December 2020

Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study

1 reference

12 December 2020

Rofecoxib increased thrombotic events in patients with colorectal adenomas.

1 reference

12 December 2020

Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib

1 reference

12 December 2020

Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec

1 reference

12 December 2020

Reporting of 6-month vs 12-month data in a clinical trial of celecoxib

1 reference

12 December 2020

Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors

1 reference

12 December 2020

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

12 December 2020

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

1 reference

12 December 2020

Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug

1 reference

12 December 2020

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

1 reference

12 December 2020

Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib

1 reference

12 December 2020

Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema

1 reference

12 December 2020

ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

12 December 2020

Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines

1 reference

12 December 2020

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

1 reference

12 December 2020

Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee

1 reference

12 December 2020

[What do we know about the cardiovascular toxicity of the NSAIDs?]

1 reference

12 December 2020

The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion

1 reference

12 December 2020

Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo

1 reference

12 December 2020

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

1 reference

12 December 2020

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

1 reference

12 December 2020

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

1 reference

12 December 2020

Tolerance to celecoxib in patients with a history of adverse reactions to nonsteroidal anti-inflammatory drugs

1 reference

12 December 2020

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

12 December 2020

Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs

1 reference

12 December 2020

Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.

1 reference

12 December 2020

Safety of celecoxib in individuals allergic to sulfonamide: a pilot study

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

Rheumatoid arthritis: an overview of new and emerging therapies

1 reference

12 December 2020

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

1 reference

12 December 2020

Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.

1 reference

12 December 2020

A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip.

1 reference

12 December 2020

Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

1 reference

12 December 2020

Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy

1 reference

12 December 2020

NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland

1 reference

12 December 2020

Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies

1 reference

12 December 2020

COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?

1 reference

12 December 2020

Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.

1 reference

12 December 2020

Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib

1 reference

12 December 2020

10.2165/00003495-200767160-00008

Identifiers

DOI

1 reference

PubMed ID

17983259

Dimensions Publication ID

3 August 2017

1027717810

0 references

Fatcat ID

release_e2y4hroc3veb5jybib4biv2ra4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e2y4hroc3veb5jybib4biv2ra4

24 November 2022

mapped directly with Wikidata item

PubMed ID

17983259

1 reference

PubMed ID

17983259